EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Selinexor potentiates NK cell activation against multiple myeloma

Daniel T Harding, Lara V Graham, Laura G Bartlett, Nancy Gudgeon, Jack G Fisher, Christopher J Walker, Trinayan Kashyap, Charlotte E Brookes, Aidan Haslam, Graham McIlroy, Guy Pratt, Ben M Amram und 5 weitere

Clinical and Experimental Immunology · 06.01.2026 · 220 (1)

DOI: 10.1093/cei/uxag059 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Immunology, online erschienen am 26.09.2026. Verfasst von Daniel T Harding und 16 weiteren Autor:innen. Beteiligte Einrichtung: School of Clinical and Experimental Sciences, University of Southampton, Southampton, UK. Hauptthemen laut MEDLINE: Multiple Myeloma, Killer Cells, Natural, Triazoles, Hydrazines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: John Goldman Fellowship, Leukaemia UK, Blood Cancer UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Selinexor is a first-in-class selective inhibitor of nuclear export targeting exportin-1 (XPO1) and approved for the treatment of multiple myeloma (MM). Selinexor has previously been shown to enhance natural killer (NK) cell activation against lymphoma cells via disruption of the NKG2A:HLA-E immune checkpoint axis. MM cell lines (L363, U266, MM.1S) and primary myeloma cells isolated from the bone marrow of patients were exposed to selinexor (50–2000 nM) with or without IFNγ or IL-6 to mimic the tumour microenvironment (TME). Surface HLA-E and total HLA class I were quantified by flow cytometry. Immunoblotting and a range of functional assays were used to examine the effect of selinexor on NK cell effector function against MM. Selinexor downregulated surface HLA-E expression on MM cell lines and primary myeloma cells. This improved the activation of NKG2A+ NK cells, NK cell-specific lysis of MM cell lines and antibody-dependent cellular cytotoxicity (ADCC) with the therapeutic antibodies daratumumab and elotuzumab. This improvement was also observed in the presence of TME-mimicking signals IFNγ and IL-6. Pre-treatment of MM cells with selinexor for 24 hours prior to daratumumab resulted in optimal ADCC. These data reveal that selinexor selectively disrupts the NKG2A:HLA-E immune checkpoint axis in MM and enhances NK cell activation and ADCC against MM cells. These findings provide a mechanistic rationale for investigating combinations of selinexor with approved therapeutic antibodies in MM and suggest that treatment timing may be an important consideration in the design of combination regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaKiller Cells, NaturalTriazolesHydrazinesLymphocyte ActivationHumansCell Line, TumorHLA-E AntigensAntibody-Dependent Cell CytotoxicityTumor MicroenvironmentNK Cell Lectin-Like Receptor Subfamily CInterferon-gammaHistocompatibility Antigens Class IKaryopherins

Stichwörter der Autor:innen

HLA-ENK cellsNKG2ASelinexorXPO1multiple myeloma

Substanzen

selinexorTriazolesHydrazinesHLA-E AntigensNK Cell Lectin-Like Receptor Subfamily CInterferon-gammaHistocompatibility Antigens Class IKaryopherins

Autor:innen und Institutionen

  • School of Clinical and Experimental Sciences, University of Southampton, Southampton, UK.
  • Department of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Karyopharm Therapeutics, Newton, MA USA.
  • Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, UK.

ORCID-Profile: Mark S Cragg, Matthew D Blunt

Förderung

  • John Goldman Fellowship
  • Leukaemia UK
  • Blood Cancer UK

Zitieren

APA

Harding, D. T., Graham, L. V., Bartlett, L. G., Gudgeon, N., Fisher, J. G., Walker, C. J., Kashyap, T., Brookes, C. E., Haslam, A., McIlroy, G., Pratt, G., Amram, B. M., Francis, G., Cragg, M. S., Khakoo, S. I., Dimeloe, S., & Blunt, M. D. (2026). Selinexor potentiates NK cell activation against multiple myeloma. Clinical and Experimental Immunology, 220(1). https://doi.org/10.1093/cei/uxag059

Vancouver

Harding DT, Graham LV, Bartlett LG, Gudgeon N, Fisher JG, Walker CJ, et al. Selinexor potentiates NK cell activation against multiple myeloma. Clinical and Experimental Immunology. 2026;220(1). doi:10.1093/cei/uxag059

BibTeX
@article{Harding2026,
  author = {Harding, Daniel T and Graham, Lara V and Bartlett, Laura G and Gudgeon, Nancy and Fisher, Jack G and Walker, Christopher J and Kashyap, Trinayan and Brookes, Charlotte E and Haslam, Aidan and McIlroy, Graham and Pratt, Guy and Amram, Ben M and Francis, Georgia and Cragg, Mark S and Khakoo, Salim I and Dimeloe, Sarah and Blunt, Matthew D},
  title = {Selinexor potentiates NK cell activation against multiple myeloma},
  journal = {Clinical and Experimental Immunology},
  year = {2026},
  volume = {220},
  number = {1},
  doi = {10.1093/cei/uxag059}
}
Kostenlos starten →